ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,930.85
1.09%
US Tech 100
20,810.80
1.19%
다우존스 지수
42,840.26
1.18%
Bitcoin
97,563.89
-0.20%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Mainz BioMed NV (MYNZ)

  7. Mainz BioMed NV (MYNZ) 뉴스

MYNZ

Mainz BioMed NV (MYNZ)

Mainz BioMed NV
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:MYNZ
일자시간출처헤드라인심볼기업
2024/12/1922:01GlobeNewswire Inc.Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening TestNASDAQ:MYNZMainz BioMed NV
2024/12/1707:29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
2024/12/1707:00GlobeNewswire Inc.Mainz Biomed Announces Closing of $8.0 Million Follow-On OfferingNASDAQ:MYNZMainz BioMed NV
2024/12/1622:00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MYNZMainz BioMed NV
2024/12/1322:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
2024/12/1314:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MYNZMainz BioMed NV
2024/12/1310:00GlobeNewswire Inc.Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq RulesNASDAQ:MYNZMainz BioMed NV
2024/12/1123:22InvestorsHub NewsWireSilexion Is Addressing the MOST COMMON Human Cancer Gene Mutation With RNAi; Recent M&As in the Field Were for Tens of Billions - $SLXNNASDAQ:MYNZMainz BioMed NV
2024/12/1122:00Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:MYNZMainz BioMed NV
2024/12/1007:11Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:MYNZMainz BioMed NV
2024/12/0923:16Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:MYNZMainz BioMed NV
2024/11/2922:45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
2024/11/2922:45GlobeNewswire Inc.Mainz Biomed Announces Stock SplitNASDAQ:MYNZMainz BioMed NV
2024/11/1607:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
2024/11/1223:09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
2024/11/1223:00GlobeNewswire Inc.Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global MarketsNASDAQ:MYNZMainz BioMed NV
2024/11/0522:00Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:MYNZMainz BioMed NV
2024/10/2121:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
2024/10/2121:01GlobeNewswire Inc.Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate UpdateNASDAQ:MYNZMainz BioMed NV
2024/10/1905:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
2024/10/1006:20Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
2024/10/0821:01GlobeNewswire Inc.Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New VersionNASDAQ:MYNZMainz BioMed NV
2024/10/0406:11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
2024/10/0121:01GlobeNewswire Inc.Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025NASDAQ:MYNZMainz BioMed NV
2024/09/1821:01GlobeNewswire Inc.Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand AmbassadorNASDAQ:MYNZMainz BioMed NV
2024/09/0417:01GlobeNewswire Inc.Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlertNASDAQ:MYNZMainz BioMed NV
2024/07/2521:01GlobeNewswire Inc.Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User ConvenienceNASDAQ:MYNZMainz BioMed NV
2024/07/0922:30AllPennyStocks.comMicro Cap Bid Up Following FDA Submission AnnouncementNASDAQ:MYNZMainz BioMed NV
2024/07/0916:01GlobeNewswire Inc.Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening TestNASDAQ:MYNZMainz BioMed NV
2024/07/0221:01GlobeNewswire Inc.Mainz Biomed Provides Half Year 2024 Corporate UpdateNASDAQ:MYNZMainz BioMed NV
 검색 관련기사 보기:NASDAQ:MYNZ

최근 히스토리

NASDAQ
QQQ
Invesco QQQ Trust Series 1
FX
USDEUR
US Dollar vs Euro
COIN
AVAXUSD
Avalanche
NYSE
XOM
Exxon Mobil
CCOM
US30
US 30
COIN
DOGEUSD
Dogecoin
NYSE
VZ
Verizon Communications
NASDAQ
GOOGL
Alphabet
USOTC
ADDYY
Adidas (QX)
COIN
BTCUSD
Bitcoin
USOTC
RHHBY
Roche (QX)
NASDAQ
NVDA
NVIDIA
NYSE
NKE
Nike
CCOM
US500
US 500
NYSE
MCD
McDonalds
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유